胸肌入路淋巴结清扫在乳腺癌Auchincloss手术中的应用

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (679 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the necessity, feasibility and efficacy of lymph node dissection through pectoralis muscle approach in Auchincloss operation of breast cancer. Methods From May 2008 to June 2013, clinical and follow-up data of 63 patients with breast cancer who underwent Auchincloss operation plus thoracic muscle approach lymph node dissection in the Affiliated Hospital of West Anhui Health Vocational College were collected, and the LevelⅢ group of lymph node metastasis and risk factors were statistically analyzed. Results Breast cancer patients had adequate surgical exposure and satisfactory lymph node dissection, LevelⅢ group of lymph node metastasis rate was 27.0%. Group LevelⅢ cancer lymph node metastasis was related to tumor size, clinical stage, axillary lymph node status, Her-2 in the cancer tissue and PDCD4 expression (all P ＜ 0.05). Large tumors, staging, axillary lymph node positive rate, its Her-2 expression in cancer tissue and lack of PDCD4 expression were the high risk factors of the LevelⅢ group lymph node metastasis. No serious complications were found in the postoperative follow-up, and the 5-year survival rate was 87.3%. Conclusion To have LevelⅢ group factors of breast cancer patients at high risk of lymph node metastasis Auchincloss surgery, and chest into the way lymph node cleaning is necessary and feasible, with curative effect affirmation.

Key words： Breast cancer Auchincloss operation Lymph nodes cleaning Fellow-up

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Lihao1 CHEN Benxin1 CAO Zhiguo1 ZHU Yunchao2

Cite this article:

ZHOU Lihao1 CHEN Benxin1 CAO Zhiguo1 ZHU Yunchao2. Application of thoracic muscle approach for lymph node dissection in Auchincloss operation of breast cancer[J]. 中国医药导报, 2019, 16(5): 122-125.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I5/122

[1] 马榕，张凯.乳腺癌行腋窝淋巴结清扫规范、争议与共识[J].中国实用普通外科杂志，2015，35（1）：69-71.
[2] Amin MB，Edge S，Greene F，et al. AJCC Cancer Staging Manual [M]. 8th ed. New York：Springer，2017.
[3] 汪洁.乳腺癌局部外科治疗美学新进展[J].上海医学，2017，38（18）：3-6.
[4] Yan CH，Simms L，Park K，et al. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer：results of an exploratory subgroup analysis of a phase Ⅲ trial [J]. J Thorac Oncol，2010，5（5）：688-695.
[5] 潘成武，肖劲松，陈刚，等.LevelⅢ组淋巴结清扫在腋下淋巴结阳性乳腺癌改良根治术中的应用[J].蚌埠医学院学报，2014，39（9）：1170-1172.
[6] Dillon MF，Advani V，Masterson C，et al. The value of level Ⅲ clearance in patients with axillary and sentinel node positive breast cancer [J]. Ann Surg，2014，249（5）：834-837.
[7] 彭德峰，赵云霞，朱正志，等.Kodama法淋巴结清扫在乳腺癌Auchincloss术中的应用[J].蚌埠医学院学报，2015， 40（11）：1482-1484.
[8] 张海峰，索文军，吕品，等.保乳手术与改良根治术治疗早期乳腺癌的效果[J].中国医药导报，2015，12（29）：78-80，84.
[9] 沈治祥，王厚明，赵林.乳腺癌Auchincloss手术加经胸肌入路锁骨下淋巴结清扫38例[J].广西中医药大学学报，2017，20（1）：18-20.
[10] 陆雪明.经胸大肌清扫Ⅲ组淋巴结在乳腺癌改良根治术中的应用[J].中国肿瘤外科杂志，2013，5（5）：326-328.
[11] Patel PK，Sinha AK，Saini S. Interneural tissue clearance in axillary dissection for breast cancer：What is the importance? [J]. Indian J Cancer，2017，54（3）：539-542.
[12] 马运平.乳腺癌改良根治术273例临床分析[J].中国药物与临床，2014，14（6）：821-822.
[13] 肖体现，吴锋，廖茂平，等.80例乳腺癌行Auchincloss手术的体会[J].贵阳中医学院学报，2013，35（5）：145-147.
[14] Kodama H，Nio Y，Iguchi C，et al. Ten-year follow-up results of a randomized controlled study comparing level-Ⅰvs level-Ⅲ axillary lymph node dissection for primary breast cancer [J]. Br J Cancer，2015，95（7）：811-816.
[15] 张桂英.早期乳腺癌前哨淋巴结活检替代腋窝淋巴结清扫的临床应用研究[J].实用癌症杂志，2017，32（4）：562-564.
[16] 郭强.保乳术联合前哨淋巴结活检术治疗老年乳腺癌的效果评析[J].当代医药论丛，2017，15（3）：50-51.
[17] 崔进军，宗林，陈松，等.乳腺癌前哨淋巴结阳性患者行LevelⅢ淋巴结清扫的临床探讨[J].右江医学，2012，40（5）：667-668.
[18] 郭晨明，吴楠，郭丽英.我国HER-2 阳性乳腺癌预后影响因素的Meta分析[J].中国普通外科杂志，2016，25（2）：264-270.
[19] 张青，李小欢，杨真，等.110例乳腺癌患者HER-2 基因扩增状况及其与临床病理特征的关系[J].中国医药导报，2013，10（11）：86-88.
[20] De Marchi T，Liu NQ，Sting C，et al. 4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer [J]. Molecular Oncology，2016，10（1）：24-39.
[21] Li JZ，Gao W，Ho WK，et al. The clinical association of programmed cell death protein 4（PDCD4） with solid tumors and its prognostic significance：a meta-analysis [J]. Mol Oncol，2016，10（1）：24-39.